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Background & aims: Few studies evaluating treatment of adolescent obesity have been published.
Therefore, long-term effects of the Go4it group treatment for obese adolescents were examined.
Methods: Obese adolescents (11e18 years) visiting an outpatient paediatric obesity clinic were randomly
assigned to 1) intervention group (Go4it) or 2) current regular care i.e. referral to a dietician in the home
care setting (controls). Linear mixed models analysis was performed to evaluate intervention effects.
Effect modiﬁcation by sex, age and ethnicity was checked. Outcome measures included body mass index
standard deviation score (BMIsds), body composition and metabolic components at 6 and 18 months
follow-up.
Results: 122 adolescents, 71 Go4it and 51 controls, with a mean BMIsds of 2.9  0.5 were randomised. At
18 months a modest signiﬁcant reduction in BMIsds (between group difference: 0.16; 95%CI: 0.30,
0.02; p ¼ .028) was observed. None of the other body composition or metabolic components showed
signiﬁcant treatment effects. Ethnicity was a signiﬁcant effect modiﬁer. Posthoc analysis showed a large
signiﬁcant reduction on BMIsds (between group difference: 0.35; 95%CI: 0.64, 0.07) at 18 months for
obese adolescents fromwestern descent, while no effect was observed for adolescents from non-western
descent. Signiﬁcant treatment effects were also observed for systolic and diastolic blood pressure, as well
as HDL cholesterol level, but only for obese adolescents from western descent.
Conclusions: Go4it showed promising long-term effects on BMIsds compared with regular care in obese
adolescents. Larger beneﬁts were achieved for adolescents of western ethnicity. This trial was registered
at www.trialregister.nl with the Netherlands Trial Register as ISRCTN27626398.
 2013 The Author. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. Open access under CC BY-NC-ND license.1. Introduction
Overweight and obesity in childhood are associated with
negative psychosocial health, orthopaedic complications, asthma,
and a strong increase inmetabolic abnormalities.1,2 Elevated insulin
levels are the ﬁrst metabolic abnormalities observed in obese
children. Insulin resistance can lead to glucose intolerance and type
2 diabetes. Child obesity also increases the risk for metabolic syn-
drome, which is a group of cardiovascular risk factors includingþ31 204444143.
teenge).
Ltd and European Society for Clinincreased waist circumference, hypertension, dyslipidaemia and
impaired fasting glucose levels.3 Therefore, the prominent public
health goal is primary prevention of child obesity. In addition,
effective treatments are required for existing child obesity, since
80% of obese children become obese adults.4,5 Notwithstanding the
high prevalence of child obesity, little evidence regarding effective
child obesity treatments has been published.6 Most studies
included 7e12 year old children, and only a few studies evaluated
treatment of adolescent obesity.6e8 Cognitive behavioural modiﬁ-
cation techniques have shown promising results regarding lifestyle
changes in child obesity,9 and were used to develop a new multi-
disciplinary group treatment for obese adolescents (Go4it).10
This study describes the long-term effect of the Go4it group
treatment for obese adolescents on anthropometrics, body compo-
sition, and metabolic components in a randomised controlled trial.ical Nutrition and Metabolism. Open access under CC BY-NC-ND license.
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2.1. Subjects and design
The present study is a randomised controlled trial evaluating the
effect of the Go4it multidisciplinary group treatment for obese
adolescents, at six and 18 months follow-up.
Adolescents were referred by their general practitioner or
school doctor to the outpatient paediatric obesity clinic of the VU
University Medical Center Amsterdam. At their ﬁrst visit the
paediatric-endocrinologist interviewed all adolescents concerning
their medical history, weight development and ethnicity.11 Subjects
were categorized as of western ethnicity when both parents were
Dutch or with at least one parent born outside the Netherlands, but
inside Europe (including former Yugoslavia and Soviet Union),
North America, Oceania, Indonesia or Japan. Subject with at least
one parent born in Turkey, Africa, Latin America or Asia were
classiﬁed as non-western. The physical examination included
height, weight, waist circumference, blood pressure and pubertal
Tanner stage.12
The subjects and their parents received an information brochure
about the study. Within two weeks, the research assistant checked
their willingness to participate. Subjects were eligible when they
met the following inclusion criteria: 1) age between 11 and 18
years; 2) overweight or obesity according to the deﬁnition of Cole
et al.13 Exclusion criteria were: not Dutch-speaking, obesity as a
result of a known syndrome or organic cause (hypothyroidism),
mental retardation, physical limitations and diagnosed type 2
diabetes mellitus. The research assistant randomly assigned sub-
jects to the intervention (60%) or control group (40%), using SPSS
for random selection. This asymmetric distribution was chosen to
recruit a sufﬁcient number of adolescents to start the intervention
sessions within a reasonable time period Randomisation was
stratiﬁed for sex and age group (11e14 y, 15e18 y). The random-
isation could not be blinded to the researcher and participants.
Recruitment of adolescents occurred from May 2006 to June 2008.
The primary outcome was BMI standard deviation score at 18
months follow-up. The medical ethical committee for human
studies of the VU University Medical Center Amsterdam approved
the protocol. Adolescents as well as their parents gave written
informed consent.
2.2. Intervention
Go4it is a multidisciplinary group treatment for obese adoles-
cents based on the programs of Braet et al.,9 Epstein et al.,7 and the
educational materials of the Dutch Obesity Intervention in Teen-
agers (DOiT).14 During 7 sessions (duration 90min) with an interval
of 2e3 weeks the adolescents received education on healthy di-
etary, sedentary and physical activity behaviour. The group sizewas
8e12 adolescents. They received cognitive behavioural therapy in
which they learned how to improve their lifestyle and how to
maintain energy balance. Go4it was carried out in an outpatient
clinic involving a dietician, paediatrician/endocrinologist and
psychologist.
In addition, two separate parallel sessions for parents were
organised corresponding with the ﬁrst and fourth session of the
adolescents. Four booster group sessions were scheduled 6, 14, 26,
and 36 weeks after the 3-months intervention period, in order to
encourage the adolescents to maintain or further improve their
energy balance behaviour and discuss problems and questions.
Throughout the program the adolescents remained in the same
peer group. The control group received the regular care in the
Netherlands (valid for year 2006e2009), consisting of referral to a
dietician in the home care setting. Adolescents had to make thisappointment themselves. We asked the control group whether
they had participated in any other treatment program during the
study period. Reasons for non compliance were collected by phone
and questionnaire. Details of the intervention, including sample
size calculation, have been published elsewhere.10
2.3. Anthropometrics, body composition and metabolic components
After an overnight fast, the subjects attended the outpatient
clinic. Height was measured with an accuracy of 0.1 cm with an
electronic stadiometer (KERN250D, De Grood Metaaltechniek,
Nijmegen, Netherlands). Body weight was measured (in under-
wear) within 0.1 kg with a calibrated electronic ﬂat scale (SECA861,
Schinkel, Nieuwegein, Netherlands). Weight and height were used
to calculate BMI (kg/m2). For calculation of BMI standard deviation
scores (BMIsds) or z-scores, a reference database of Dutch children
was used (www.growthanalyser.org; version 3.5). Waist circum-
ference was measured and recorded with a ﬂexible band to an
accuracy of 0.1 cm. Body composition was assessed with dual en-
ergy x-ray absorptiometry (DXA; Hologic QDR4500-Delphi, Tromp
Medical, Castricum, Netherlands). A standard oral glucose tolerance
test was performed by a research nurse.3 Baseline samples were
obtained for measurement of fasting glucose, fasting insulin and
lipids. Glucose was given orally (1.75 g/kg body weight, up to a
maximum of 75 g glucose). Blood samples were drawn after 30 and
120 min. Pre-diabetes was deﬁned according the American
Diabetes Association (ADA) guidelines as impaired fasting glucose
(IFG 5.6e6.9 mmol/l) and/or impaired glucose tolerance (IGT 7.8e
11.1 mmol/l).15 Insulin resistance was estimated by the homeostatic
model assessment (HOMA-IR ¼ (fasting insulin in mU/l  fasting
glucose in mmol/l)/22.5). Systolic and diastolic blood pressures
were measured at the left arm after a 10-min rest in supine
position.
Themetabolic syndromewas deﬁned following IDF guidelines.16
For adolescents aged 10 years or older the metabolic syndrome is
diagnosed whenwaist circumference is above the 90th percentile17
in combination with the presence of 2 or more clinical features
(fasting triglycerides>1.7mmol/l; fasting HDL<1.03mmol/l; blood
pressure >130 mmHg systolic or >85 mmHg diastolic; fasting
glucose > 5.6 mmol/l). For adolescents aged 16 years and older the
adult IDF criteria were used. The adult deﬁnition is the same as for
children, except for fasting HDL in females (fasting HDL <1.29).
2.4. Statistics
Baseline characteristics were analysed by t test for continuous
variables and Chi square test for categorical variables. Group
comparisons were performed according the intention-to-treat
principle whereby all subjects were analyzed in the group to
which they were randomly assigned. Linear mixed models were
applied to assess the effect of the intervention over time. A random
intercept and a random slope with time were assumed. Age-, sex-
and, ethnicity adjusted analyses were performed with intervention
as categorical variable and time as continuous variable, with an
interaction term for intervention and time. B coefﬁcients, 95%
conﬁdence intervals, and p values were calculated. This approach
increases statistical power as it accounts for within-person corre-
lation over time and includes all assessments, at baseline as well as
at 6 and 18 months. A p value of < 0.05 was considered statistically
signiﬁcant. Effect modiﬁcation by sex, age and ethnicity was
checked by adding an interaction term between group allocation
and the potential moderator. A P value of < 0.1 was considered
statistically signiﬁcant. In case effect modiﬁcation was found, sub-
group analyses were performed. Data were analysed using SPSS
software (version 18$0, 2009 SPSS Inc., Chicago, Illinois, USA).
Table 1
Baseline characteristics in intervention (Go4it) and control group.
Intervention
group (n ¼ 71)
Control
group (n ¼ 51)
p
Sex, n 0.56d
Male 33 21
Female 38 30
Age, years 14.5 (1.7)a 14.4 (1.8) 0.73c
Weight, kg 94.7 (18.4) 92.2 (18.5) 0.47c
Weight sds 3.03 (0.81) 2.96 (0.88) 0.65c
Height, cm 167.9 (9.6) 165.0 (8.2) 0.08c
Height sds 0.17 (1.1) 0.05 (0.93) 0.24c
Body mass index, kg/m2 33.3 (4.6) 33.6 (5.1) 0.73c
Body mass index sds 2.93 (0.41) 2.93 (0.51) 0.99c
Degree of overweight, n 0.221d
Overweight 5 7
Obese 66 44
Ethnicity, n 0.09d
Western 36 18
Non-western 35 33
Prediabetes
Impaired fasting glucose 6 3 0.60d
Impaired glucose tolerance 4 2 0.63d
Tanner stage, nb 0.47d
Pre-pubertal (stage 1) 25 16
Pubertal (stage  2) 40 34
a Values are means (SD).
b For Tanner stage missing values were 6 for intervention and 1 for control group.
c t-test.
d ChieSquare test.
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Figure 1 shows the consort diagram for the Go4it trial. Of the 219
adolescents who were assessed for eligibility, 122 consented to the
trial and were randomly (60:40) assigned to the intervention
(n¼ 71) and control group (n¼ 51). At 18months two subjects from
the control group were excluded from the analyses, one developed
type 1 diabetes and another was diagnosedwith acute rheumatism,
and therefore met exclusion criteria. Linear mixed models were
applied whereby all subjects were analyzed in the group to which
they were randomly assigned.
Table 1 shows baseline characteristics of the 122 subjects (56%
girls). At six months follow-up 80% were reassessed and at 18
months follow-up 56%. Baseline characteristics were not signiﬁ-
cantly different between study completers and dropouts.
Table 2 shows the change in anthropometrics and body
composition as well as metabolic components. The primary
outcome BMIsds was signiﬁcantly reduced in the go4it group at 18
months follow-up (between group difference: 0.16; 95%
CI: 0.30;0.02). Concretely, in the intervention group (n ¼ 36)
BMIsds decreased from 2.96 at baseline to 2.86 at 18 months
follow-up, while in the control group (n ¼ 32) BMIsds increased
from 2.91 to 2.96. None of the other body composition or metabolic
components showed signiﬁcant treatment effects.
But according to pre-diabetes, there were two subjects less in
the intervention group, while in the control group two more sub-
ject were considered pre-diabetic after 18 months follow-up.
Furthermore, the subjects with lower BMIsdswere related to the
subjects with lower HOMA-IR at 18 months versus baseline
(p ¼ .054).Fig. 1. Flowchart for enrolment, randomisation, and follow-up of study participants.
Table 2
Mean values for anthropometrics, body composition, and metabolic components at baseline, 6 and 18 months for intervention and control group, as well as between group
difference (intervention group versus control group) at 6 and 18 months.
Baseline 6 months 18 months Between group
difference at 6 month
Between group
difference at 18 months
Weight, kg Intervention 94.7  18.4a 95.9  17.7 102.5  19.4 2.05 (4.98; 0.88)b 2.09 (5.33; 1.14)c
Control 92.2  18.5 95.1  18.8 99.3  18.8
Weight sds Intervention 3.03  0.81 2.96  0.85 3.01  0.89 0.12 (0.28; 0.05) 0.07 (0.03; 0.17)
Control 2.96  0.88 2.95  0.96 2.85  1.0
Height, cm Intervention 167.9  9.6 170.5  8.6 173.1  19.4 0.51 (0.30; 1.32) 0.99 (0.06; 1.92)
Control 165.0  8.2 166.3  7.5 168.3  7.3
Height sds Intervention 0.17  1.06 0.25  0.99 0.28  1.05 0.07 (0.03; 0.17) 0.08 (0.20; 0.18)
Control 0.05  0.93 0.23  0.88 0.25  0.97
Body Mass Index, kg/m2 Intervention 33.3  4.6 32.8  4.7 34.2  6.1 0.76 (1.74; 0.22) 0.97 (2.02; 0.09)
Control 33.6  5.1 34.2  5.3 34.9  5.6
Body Mass Index sds Intervention 2.93  0.41 2.81  0.50 2.86  0.7 0.10 (0.23; 0.04) L0.16 (L0.30; L0.02)
Control 2.93  0.51 2.95  0.55 2.96  0.6
Waist circumference, cm Intervention 2.93  0.41 108.4  12.2 112.6  15.9 3.02 (6.33; 0.29) 2.91 (6.62; 0.80)
Control 2.93  0.51 111.9  13.1 115.2  12.9
Trunk fat, kg Intervention 108.1  12.4 16.9  5.1 16.4  5.2 0.49 (1.70; 0.72) 0.88 (2.24; 0.48)
Control 108.6  11.2 16.9  4.5 16.7  5.6
Total fat, kg Intervention 17.3  4.8 38.2  9.2 37.3  9.8 1.13 (3.38; 1.12) 1.69 (4.24; 0.86)
Control 16.8  4.5 38.4  8.4 37.3  9.9
Appendicular muscle mass, kg Intervention 38.8  8.7 26.0  4.9 28.1  5.0 0.13 (0.74; 0.48) 0.24 (0.85; 0.37)
Control 37.9  8.6 24.4  4.3 25.3  4.6
Fasting glucose, mmol/l Intervention 25.2  5.4 5.0  0.4 5.3  0.5 0.07 (0.47; 0.32) 0.15 (0.02; 0.33)
Control 24.1  4.6 5.1  0.4 5.0  0.4
Glucose 120 min, mmol/l Intervention 5.0  0.4 5.9  1.0 5.9  1.1 0.01 (0.87; 0.88) 0.05 (0.56; 0.46)
Control 5.0  0.4 6.0  1.3 6.1  1.3
Fasting insulin, pmol/l Intervention 5.9  1.1 127  54 118  66 0.30 (22; 21) 0.93 (23; 25)
Control 6.0  0.9 132  62 122  57
Insulin 30 min, pmol/l Intervention 125  63 1163  611 1115  858 265 (586; 55) 262 (634; 109)
Control 133  75 1379  1119 1387  941
Insulin 120 min, pmol/l Intervention 1280  610 565  366 611  513 23 (193; 148) 1 (206; 203)
Control 1177  804 605  493 660  520
HOMA-IR Intervention 661  424 4.8  2.3 5.7  2.7 0.08 (0.98; 0.82) 0.16 (1.08; 0.76)
Control 671  404 5.0  2.4 4.6  2.2
Systolic blood pressure, mmHg Intervention 4.7  2.6 112  14 114  10 1.54 (2.80; 5.89) 2.78 (7.86; 2.31)
Control 5.0  3.0 110  12 115  10
Diastolic blood pressure, mmHg Intervention 113  13 62  8 64  8 0.41 (3.46; 2.63) 0.84 (2.70; 4.37)
Control 112  13 62  7 63  11
HDL, mmol/l Intervention 63  8 1.12  0.22 1.13  0.19 0.02 (0.04; 0.08) 0.07 (0.001; 0.14)
Control 62  8 1.13  0.19 1.10  0.28
Triglycerides, mmol/l Intervention 1.15  0.25 1.08  0.59 0.99  0.49 0.06 (0.09; 0.21) 0.08 (0.26; 0.09)
Control 1.19  0.22 1.00  0.42 1.06  0.58
The interaction of intervention*time was not signiﬁcant for any of the outcome measurements, implying that the estimated time effect did not differ signiﬁcantly by
intervention. Number of observations varied at 6months from 49 to 53 in the intervention group and from 40 to 44 in the control group. Numbers of observations varied at 18
months from 33 to 36 in the intervention group and from 27 to 32 in the control group.
a Mean (sd).
b B (95%CI) adjusted for age, sex and ethnicity; bold type indicates P < .05.
c Group comparisons were performed according the intention-to-treat principle with all subjects analyzed in the group to which they were randomly assigned. Linear
mixedmodels analysis was used to assess the effect of the intervention over time adjusted for age, sex and ethnicity. Therefore, it is not possible to calculate the between group
difference based on Table 2. This method includes all assessments, at baseline as well as at 6 and 18 months.
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months (p ¼ .029) and 18 months (p ¼ .057). Table 3 shows the
results stratiﬁed for ethnicity. The treatment effect was signiﬁcant
in adolescents from western descent (0.35; 95%CI: 0.64; 0.07)
but not in those from non-western descent (0.004; 95%CI: 0.14;
0.15). Signiﬁcant treatment effects were also observed for systolic
and diastolic blood pressure, as well as HDL cholesterol level, but
only for obese adolescents from western descent.
Concerning compliance, 42 of the 71 subjects in the inter-
vention group, attended at least ﬁve Go4it sessions. The reasons
for not attending the Go4it sessions included lack of motivation
to change dietary habits, lack of belief of parents in their child’s
possible success to lose weight, previous unsuccessful dieting
experiences, travel distance and the limited time of working
parents and schoolchildren. Seven of the 29 subjects who
attended less than ﬁve sessions never started the Go4it program.
Of the parents 72% attended the ﬁrst parent session and 55%
attended the second parent session. At 6 months, 21 (48%)subjects in the control group had never visited a dietician, 4
subjects visited a dietician once, 6 twice, 7 three or more times,
and for 6 subjects it is unknown. The main reported reason for
not making an appointment was lack of motivation because of
previous unsuccessful dieting experiences with or without a
dietician.
The participants of the control group had not participated in any
other treatment program during the 18 months follow-up.
4. Discussion
The multidisciplinary group treatment Go4it signiﬁcantly
reduced the standardised Body Mass Index (BMIsds) at 18 months
in obese adolescents. The overall effect was a reduction in BMIsds of
0.16. Ethnicity signiﬁcantly modiﬁed this treatment effect, with a
signiﬁcant BMIsds reduction of 0.35 in obese adolescents of
western descent versus no signiﬁcant treatment effect in those of
non-western descent.
Table 3
Mean values for anthropometrics, body composition, and metabolic components at baseline for intervention and control group, separated for Western (Go4it n ¼ 36, Control
group n ¼ 18) and NonWestern adolescents (Go4it n ¼ 35, Control group n ¼ 33), as well as between group difference (intervention group versus control group) at 18 months.
Western Non western Western ethnicity Non-western ethnicity
Weight, kg Intervention 97.5  17.4 91.7  19.2a 7.66 (13.47; 1.84)b 2.20 (1.64; 6.04)
Control 86.0  16.3 95.5  19.0
Weight sds Intervention 3.08  0.76 2.97  0.86 0.17 (0.48; 0.14) 0.07 (0.26; 0.11)
Control 2.66  0.81 3.12  0.88
Height, cm Intervention 170.7  8.8 165.2  8.8 0.60 (1.85; 0.65) 1.77 (0.49; 3.04)
Control 166.2  10.2 164.3  7.0
Height sds Intervention 0.28  1.02 0.06  1.10 0.08 (0.07; 0.22) 0.06 (0.08; 0.20)
Control 0.16  0.95 0.16  0.92
Body Mass Index, kg/m2 Intervention 33.3  4.6 33.3  4.6 L2.54 (L4.32; L0.76) 0.39 (0.91; 1.69)
Control 31.0  4.2 35.1  5.0
Body Mass Index sds Intervention 2.91  0.44 2.95  0.38 L0.35 (L0.64; L0.07) 0.004 (0.14; 0.15)
Control 2.67  0.53 3.07  0.45
Waist circumference, cm Intervention 109.6  13.8 106.6  10.9 L5.80 (L11.1; L0.46) 1.10 (6.30; 4.11)
Control 108.0  9.9 108.9  11.9
Trunk fat, kg Intervention 18.6  4.9 15.9  4.3 1.98 (4.25; 0.30) 0.19 (1.53; 1.94)
Control 15.6  4.4 17.5  4.5
Total fat, kg Intervention 41.0  8.9 36.5  8.0 L4.25 (L8.39; L0.10) 0.71 (2.57; 3.99)
Control 34.9  7.3 39.7  8.9
Appendicular muscle mass, kg Intervention 25.9  5.3 24.4  5.5 0.98 (2.29; 0.34) 1.13 (0.24; 2.01)
Control 23.4  4.9 24.5  4.4
Fasting glucose, mmol/l Intervention 5.0  0.3 5.0  0.4 0.31 (0.01; 0.62) 0.03 (0.20; 0.25)
Control 4.9  0.3 5.0  0.5
Glucose 120 min, mmol/l Intervention 5.8  1.1 6.0  1.1 0.20 (1.00; 0.61) 0.26 (0.43; 0.94)
Control 6.3  1.1 5.9  1.1
Fasting insulin, pmol/l Intervention 125  59 125  68  1 (37; 36) 10 (25; 44)
Control 98  58 151  77
Insulin 30 min, pmol/l Intervention 1297  615 1266  613 130 (648; 389) 349 (895; 196)
Control 1046 625 1249  887
Insulin 120 min, pmol/l Intervention 608  380 713  464 26 (252; 304) 37 (264; 339)
Control 671  486 671  359
HOMA-IR Intervention 4.69  2.36 4.76  2.90 0.24 (1.23; 1.72) 0.22 (1.25; 1.69)
Control 3.62  2.19 5.74  3.19
Systolic blood pressure, mmHg Intervention 111  13 114  13 L9.3 (L17.7; L0.9) 0.4 (6.3; 7.0)
Control 111  10 113  14
Diastolic blood pressure, mmHg Intervention 63  8 62  7 L6.6 (L12.9; L0.3) 5.4 (1.4; 9.6)
Control 61  7 62  9
HDL cholesterol, mmol/l Intervention 1.11  0.25 1.20  0.24 0.16 (0.02; 0.30) 0.01 (0.07; 0.09)
Control 1.17  0.24 1.21  0.24
Triglycerides, mmol/l Intervention 1.16  0.66 0.98  0.60 0.19 (0.51; 0.13) 0.03 (0.25; 0.19)
Control 1.40  0.55 0.90  0.30
The interaction of intervention*time was not signiﬁcant for any of the outcome measurements, implying that the estimated time effect did not differ signiﬁcantly by
intervention.
a Mean (sd), bold type indicates P < .05.
b B (95% CI) adjusted for age, sex and ethnicity; bold type indicates P < .05.
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for a number of reasons. First, the intervention aimed to raise en-
ergy balance behaviour consciousness of the participants and
change their behaviour in a way that would result in long-term
beneﬁcial effects. This matter is of particular importance since
most initial and short-term results in weight management disap-
pear over time.5 The present intervention showed a gradual BMIsds
change over time, with a larger effect at 18 months versus 6
months, indicating an increase with time rather than a decrease
with time. Second, Go4it was intended as a relatively low intensive
low cost outpatient program that would be relatively easy to
implement in the child health care and primary health care setting.
The Go4it intervention was still able to generate a long-term effect
(0.16 BMIsds) that is essentially the same as e.g. the more inten-
sive intervention by Savoye et al. (0.16 BMIsds).18 Third, for the
obese adolescents from western descent the effect size was larger
than expected (12% vs 10%). Moreover, signiﬁcant treatment effects
in adolescents from western descent on body composition and
metabolic components (systolic and diastolic blood pressure and
HDL cholesterol level) show that the effect on BMIsds is not an
accidental ﬁnding, but a consistent improvement in outcome pa-
rameters relevant for future health of obese adolescents. This is inline with the observations of Ford et al. that improvements in body
composition and metabolic components in obese adolescents can
be expected with BMIsds reduction of 0.25.19 This is of particular
importance since severely obese adolescents (BMIsds > 2.5) with
pre-diabetes are at very high risk of developing type 2 diabetes.20
At 18 months, in comparison with baseline, in the control group
two additional subjects were considered prediabetic, while in the
intervention group two subjects improved from prediabetic to
‘normal’.
There are only 6 comparable randomised controlled trials
evaluating treatment programs for obese adolescents.21e25 The
2009 Cochrane review on treatment programs for obese children
included 64 randomised controlled trials.6 Seventeen of the 64
studies included adolescents, based on a mean age at or above
12 years. Twelve of the 17 studies were lifestyle interventions with
a behavioural component as the main focus of the intervention.
Seven of the 12 studies were pooled in a meta-analysis, which
showed a BMIsds change of 0.14 at 12 months. One of the 7
studies had a follow up period longer than 12 months, and
showed that the signiﬁcant effect of the internet-based behav-
ioural program at 12 months was not sustained up to 18 and 24
months.25
G.H. Hofsteenge et al. / Clinical Nutrition 33 (2014) 385e391390The present study can be compared to the randomised
controlled trial in obese children 8e16 years of age by Savoye
et al.,18,23 although the age group is younger and BMIsds lower
(þ2.5 vs þ3). Savoye et al. compared the effect of an intensive
lifestyle intervention program to a control group at 12 and 24
months. The intervention group received a family-based program,
including exercise, nutrition, and behaviour modiﬁcation. Lifestyle
sessions were offered twice weekly for the ﬁrst 6 months, then
twice monthly for the second 6 months and no active intervention
for the last 12 months. The control group received counselling
every 6 months. The intervention by Savoye et al. resulted in a
signiﬁcant long-term (24 months) effect of 0.16 BMIsds, which is
identical to the effect of 0.16 for Go4it at 18 months.18 The
advantage of Go4it was the lower intensity, and therefore lower
cost, with 11 sessions for Go4it versus 60 sessions for Savoye et al.18
Nguyen et al. reported on a randomised controlled trial in obese
adolescents of 13e16 years of age, although again with a lower
BMIsds compared to the present study (þ2 versus þ3).26 Nguyen
et al. compared the effect of a lifestyle modiﬁcation program
(Loozit) with or without 2-weekly additional therapeutic contact,
including telephone coaching and short-message-service. The
Loozit intervention consisted of 7 weekly sessions, including par-
ents, during the initial twomonths, and 3-monthly booster sessions
up to 24 months (in total 14 sessions). The effect of Loozit, with or
without additional therapeutic contact, on BMIsds was 0.13 at 24
months. This intervention showed a slightly smaller effect size,
while based on a higher intensity (14 vs 11 sessions) and longer
intervention period (24 vs < 12 months, including booster ses-
sions). Overall the long-term effect size of the Go4it intervention
appears to be in line with, or even more favourable than, other
interventions for obese adolescents.
This study has several strengths and original features including:
the randomised controlled trial design, long-term follow-up, a
relatively easy to implement intervention, and robust outcome
measures (including body composition measured by DXA and
metabolic components).
The main limitation of the present trial is the high level of
attrition, which was 44% (49% in the intervention group and 37% in
the control group) at 18 months. Ball et al. recently showed that
even on the short term an attrition rate of 20e40%was found in this
target group.27 Also, Nguyen et al. reported 38% and Savoye et al.
even 56% attrition.18,26 Therefore, this level of attrition is compa-
rable to other studies concerning obesity treatment in adolescents
(12e47%).18,21e28 Data imputation was not performed because
subjects were in their mid-to-late puberty; therefore increases in
height and weight were expected. By imputation of data a some-
what misleading estimate of the intervention effect would be
provided.
Another limitations are the asymmetrical randomization. The
main reason for this asymmetrical randomization was that to start
the group sessions as soon as possible after the ﬁrst included
adolescent was enrolled into the study. Otherwise it would have
taken several months before a sufﬁcient number of adolescents had
enrolled to start the group sessions.
Disappointing was the lack of a signiﬁcant treatment effect in
non-western obese adolescents, despite tailoring the nutrition
education and advice of Go4it to the different ethnicities. Potential
explanations are that parents from Turkish or Moroccan descent
underestimate the actual weight status of their children as well as
the resulting health effects. Thus, cultural norms of healthy body
weight and attractive appearance are probable causes of the
observed difference.29 Savoye et al. also studied a culturally diverse
group of children, but did not report on effect-modiﬁcation.18
Beforehand, it was intended to develop an intervention that is
implementable into the child health care and primary health caresetting. This affected choices in the design of the intervention,
which had to be evidence based and effective but also practical and
affordable. For instance, there was no exercise program provided,
but participants were encouraged to seek and participate in
existing exercise programs in their own neighborhood. The inter-
vention could have been upgraded with telephone coaching, short-
message-service, and email communication at low cost. However,
Nguyen et al. showed that this additional therapeutic contact did
not improve the outcome at 24 months.30 Since travel distance and
the limited time of working parents and schoolchildren was one of
the main reasons for non-compliance, implementation of the
intervention nearby home or school may improve compliance.
5. Conclusions and implications
In summary, the Go4it intervention showed a signiﬁcant long-
term effect on BMIsds, compared to current regular care in obese
adolescents. Implementation of Go4it in a setting nearby home or
school may even improve successful treatment of obese adoles-
cents. In addition, development of additional programs aimed at
the non-western ethnic group is urgently required.
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